



Quarterly Report on Completed Drug Submission Reviews

Last Updated April 2026

The *Quarterly Report on Completed Drug Submission Reviews* report is divided into three reports for each year¹:

1. The *Type, Timelines and Number of Completed Drug Submission Reviews, by Quarter* reports provide detailed information on the type of drug review, the target and actual timelines for each review, the total number of reviews, and the percentage of reviews that are completed and result in a PharmaCare coverage decision within the specific timeline for the given year.
2. The *Drug Review Decisions Summary* reports provide detailed information on the Ministry's coverage decision for each drug that PharmaCare has reviewed in the given year.
3. The *Patient and Caregiver Input Summary* provides information on the number of responses to the Ministry's call for patient, caregiver and patient group input for each drug that PharmaCare has reviewed in the given year. Responses are collected via the PharmaCare [Your Voice](#) website.

Contents

2025 Reports.....	6
Type, Timelines, and Number of Completed Drug Submission Reviews, by Quarter.....	6
2025 Drug Review Decisions Summary	7
2025 Patient and Caregiver Input Summary	11
2024 Reports.....	15
Type, Timelines, and Number of Completed Drug Submission Reviews, by Quarter.....	15
2024 Drug Review Decisions Summary	16
2024 Patient and Caregiver Input Summary	20
2023 Reports.....	23
Type, Timelines, and Number of Completed Drug Submission Reviews, by Quarter.....	23
2023 Drug Review Decisions Summary	24
2023 Patient and Caregiver Input Summary	29

2026 Reports

Type, Timelines, and Number of Completed Drug Submission Reviews, by Quarter

Reporting Period	Review Type ¹	Target Timeline (months)	Reviews Completed ²	Actual Review Times (months)			Reviews Meeting Target Timeline (%)
				Avg.	Min.	Max.	
Q1 2026	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	1	39.76	39.76	39.76	0%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	6	20.91	10.32	25.82	16.67%
	Other ³	N/A	10	N/A	N/A	N/A	N/A
2026 YTD Total	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	1	39.76	39.76	39.76	0%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	6	20.91	10.32	25.82	16.67%
	Other	N/A	10	N/A	N/A	N/A	N/A
	Submissions with Timeliness ⁴	6-12	7	19.93	10.32	39.76	14.29%

¹ Review types are defined in "[The Drug Review Process in B.C. – Detailed](#)" on the PharmaCare website.

² A submission review is complete on the date of the formulary decision or the coverage effective date.

³ The 'Other' category covers submissions not subject to target timelines.

2026 Drug Review Decisions Summary

	Generic Name	Trade Name	Indication	Submission Type	Decision Date	Decision
Q1	NanoQ pen needles	NanoQ pen needles	Diabetic supplies	New Submission	2026-01-15	Regular Benefit
	SubQ Pen Needles		Diabetes, type 1	Device Submission	2026-01-15	Regular Benefit
	captopril (Oral Solution)	Noyada	hypertension, heart failure, left ventricular	Line extension	2026-01-28	Limited Coverage

		dysfunction after MI, and diabetic nephropathy, in patients having trouble swallowing pills.			
ethambutol	Etibi	Non-Tuberculous Mycobacteria	Ministry Initiated	2026-02-04	Regular Benefit
epinephrine	Emerade and Allerject	discontinuations and delistings 2982-3690-3737	Ministry Initiated	2026-02-06	Non-benefit
insulin aspart	Trurapi	diabetes mellitus	Line Extension	2026-03-01	Regular Benefit
National PharmaCare Diabetes HMT and Contraceptives (Multiple Drugs)		Diabetes HMT and Contraceptives	Ministry Initiated	2026-03-01	Regular Benefit
insulin regular	Humulin R Kwikpen	Diabetes	Ministry Initiated	2026-03-01	Regular Benefit
omalizumab inj	Omlyclo	Chronic idiopathic urticaria (CIU), allergic asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP)	Biosimilar	2026-03-04	Limited Coverage
sotatercept	Winrevair	Pulmonary arterial hypertension (WHO group 1)	New Submission	2026-03-11	Limited Coverage
mepolizumab	Nucala	severe chronic rhinosinusitis with nasal polyps	New Submission	2026-03-11	Non-Benefit
etranacogene dezaparvovec	Hemgenix	Hemophilia B	New Submission	2026-03-16	EDRD

	ravulizumab	Ultomiris	Generalized Myasthenia Gravis	Re-submission	2026-03-25	Non-Benefit
	rozanolixizumab	Rystiggo	Generalized myasthenia gravis (gMG).	New Submission	2026-03-25	EDRD
	zilucoplan	Zilbrysq	Generalized myasthenia gravis (gMG)	New Submission	2026-03-25	EDRD
	denosumab	Osenvelt		Biosimilar	2026-03-25	Palliative Care Benefit
	denosumab	Stoboclo	Postmenopausal Osteoporosis, Treatment to Increase Bone Mass	Biosimilar	2026-03-25	Limited Coverage

2026 Patient and Caregiver Input Summary

Drug Details			Patient Responses to calls for input		
Generic Name	Trade Name	Indication	Patient	Caregiver	Patient Group
caplacizumab	Cablivi	Indication: acquired thrombotic thrombocytopenic purpura (aTTP)	0	0	1
pegcetacoplan	Empaveli	Indication: C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis	1	0	1
vosoritide	Voxzogo	Indication: For the treatment of achondroplasia in pediatric patients whose epiphyses are not closed.	0	20	1
sarilumab	Kevzara	Indication: adult patients with polymyalgia rheumatica (PMR)	0	0	2

tezepelumab	Tezpire	Indication: Chronic rhinosinusitis with nasal polyps (CRSwNP)	0	0	0
tirzepatide	Mounjaro	Indication: Type 2 diabetes mellitus	24	2	1
fluorouracil sodium	Tolak	Indication: actinic keratosis (AK)	1	0	0
beclomethasone dipropionate, glycopyrronium (as bromide) and formoterol fumarate dihydrate	Trimbow	Indication: Chronic obstructive pulmonary disease (COPD) in adults	0	1	0

2025 Reports

Type, Timelines, and Number of Completed Drug Submission Reviews, by Quarter

Reporting Period	Review Type ¹	Target Timeline (months)	Reviews Completed ²	Actual Review Times (months)			Reviews Meeting Target Timeline (%)
				Avg.	Min.	Max.	
Q1 2025	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	4	8.14	5.65	8.98	100%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	2	18.11	15.09	21.13	0%
	Other ³	N/A	3	N/A	N/A	N/A	N/A
Q2 2023	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	2	16	3.03	28.98	50%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	3	23.91	14.49	28.75	0%
	Other	N/A	7	N/A	N/A	N/A	N/A
Q3 2023	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	0	N/A	N/A	N/A	N/A
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	7	15.96	11.03	25	14.29%
	Other	N/A	6	N/A	N/A	N/A	N/A
Q4 2023	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	8	15.13	3.82	22.07	25%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	9	17.23	9.43	36.07	22.22%
	Other	N/A	5	N/A	N/A	N/A	N/A
2025 YTD Total	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	14	13.09	3.03	28.98	50%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	21	18.80	9.43	36.07	14.29%
	Other	N/A	21	N/A	N/A	N/A	N/A
	Submissions with Timeliness ⁴	6-12	35	16.01	3.03	36.07	28.57%

¹ Review types are defined in "[The Drug Review Process in B.C. – Detailed](#)" on the PharmaCare website.

² A submission review is complete on the date of the formulary decision or the coverage effective date.

³ The 'Other' category covers submissions not subject to target timelines.

2025 Drug Review Decisions Summary

	Generic Name	Trade Name	Indication	Submission Type	Decision Date	Decision
Q1	efgartigimod alfa (EDRD)	Vyvgart	Generalized myasthenia gravis (gMG).	New Submission	January 8, 2025	EDRD
	Strefa Pen Needles	Strefa Pen Needles	diabetes	Diabetic Supplies	January 8, 2025	Eligible benefit
	infliximab	Remsima SC	RA	Ministry Initiated	January 21, 2025	Limited Coverage
	infliximab	Remsima	Chron's Disease	New Submission	January 21, 2025	Limited Coverage
	infliximab	Remsima	Ulcerative Colitis	New Submission	January 21, 2025	Limited Coverage
	secukinumab 150 mg/mL pre-filled syringe	Cosentyx	Line Extension	Line Extension	January 28, 2025	Limited Coverage
	cariprazine	Vraylar	Schizophrenia	Re-submission	February 4, 2025	Limited Coverage
	estradiol	Vagifem	contraceptive	Ministry Initiated	March 5, 2025	Non-Benefit
	palovarotene (EDRD)	Sohonos	Fibrodysplasia Ossificans Progressiva	New Submission	March 20, 2025	EDRD
	sacubitril/valsartan	Entresto	Revise LCC	Ministry Initiated	25-Mar-25	Limited Coverage
Q2	infliximab injection	Ixifi	Rheumatoid arthritis Ankylosing spondylitis Crohn's disease – adult and pediatric Fistulising Crohn's disease Ulcerative colitis – adult and pediatric	Biosimilar	April 1, 2025	Limited Coverage

		Psoriatic arthritis Plaque psoriasis			
infliximab	Remdantry	ulcerative colitis, crohns disease, rheumatoid arthritis	New Submission	April 1, 2025	Limited Coverage
maribavir	Livtency	Post-transplant cytomegalovirus infection	New Submission	April 3, 2025	Limited Coverage
deferiprone (Line Extension)	FERRIPROX (Modified- Release)	transfusional iron overload	Line Extension	April 24, 2025	Non- Benefit
riociguat	generics	Chronic thromboembolic pulmonary hypertension	Ministry Initiated	May 1, 2025	Limited Coverage
cenobamate	Xcopri	partial-onset seizures	Resubmission	May 20, 2025	Limited Coverage
lacosamide	Generics	Epilepsy, partial-onset seizure	Ministry Initiated	May 20, 2025	Limited Coverage
tocilizumab	Tyenne	rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis ,active systemic juvenile idiopathic arthritis	Biosimilar	May 27, 2025	Limited Coverage
inebilizumab	Uplizna	Neuromyelitis optica spectrum disorders (NMOSD)	New Submission	May 28, 2025	Non- Benefit
anifrolumab	Saphnelo	Systemic lupus erythematosus	New Submission	June 4, 2025	Limited Coverage
belimumab	Benlysta	Lupus nephritis	New Submission	June 11, 2025	Non- Benefit
mesalamine	Mezera - 500 mg tablet, 1g rectal suppository, 1g/actuation rectal foam enema	ulcerative colitis	Line Extension	June 18, 2025	Regular Benefit

Q3	eplontersen	Wainua	Polyneuropathy in hereditary transthyretin-mediated amyloidosis	New Submission	July 8, 2025	EDRD
	upadacitinib	Rinvoq AS	ankylosing spondylitis	New Submission	July 16, 2025	Non-Benefit
	tofacitinib	generics	PsA and AS	Therapeutic Review	July 16, 2025	Limited Coverage
	bimekizumab	Bimzelx	Ankylosing spondylitis	New Submission	July 16, 2025	Limited Coverage
	bimekizumab	Bimzelx	Psoriatic arthritis	New Submission	July 16, 2025	Limited Coverage
	bimekizumab	Bimzelx	Moderate to severe plaque psoriasis (PsO) in adult patients who are candidates for systemic therapy or phototherapy.	Line extension	July 16, 2025	Limited Coverage
	methylphenidate hydrochloride	Foquest	Attention deficit hyperactivity disorder (ADHD)	Line Extension	July 23, 2025	Limited Coverage
	setmelanotide (EDRD)	Imcivree	Bardet-Biedl syndrome	New Submission	July 29, 2025	EDRD
	secukinumab	Cosentyx	Hidradenitis suppurativa	New Submission	August 13, 2025	Limited Coverage
	Freestyle Libre 3 Plus	Freestyle Libre 3 Plus	Flash Glucose Monitoring System	Device Submission	August 20, 2025	Limited Coverage
	edoxaban	generics	atrial fibrillation and venous thromboembolism (VTE)	Ministry Initiated	September 4, 2025	Regular Benefit
	insulin icodec	Awikli	Diabetes mellitus, type 2	New Submission	September 10, 2025	Non-benefit
	ravulizumab	Ultomiris	anti-aquaporin 4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).	EDRD	September 16, 2025	Non-Benefit

Q4	danicipan	Voydeya	Paroxysmal nocturnal hemoglobinuria (PNH)	New Submission	06-Oct-25	Non-Benefit
	evinacumab (EDRD)	Evkeeza	Homozygous familial hypercholesterolemia (HoFH)	New Submission	October 7, 2025	EDRD
	metreleptin	Myalepta	Leptin deficiency in lipodystrophy	New Submission	October 21, 2025	EDRD
	maralixibat (EDRD)	Livmarli	Alagille syndrome	New Submission	October 30, 2025	EDRD
	isotretinoin	ABSORICA LD	severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne	Line Extension	November 5, 2025	Non-benefit
	isotretinoin capsules	EPURIS	severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne.	Line Extension	November 5, 2025	Non-benefit
	pegvaliase	Palynziq	Phenylketouria	New Submission	November 12, 2025	Non-benefit
	burosumab	Crysvita	Treatment of X-Linked Hypophosphatemia	Re-Submission	12-Nov-25	EDRD
	etrasimod	Velsipity	Ulcerative colitis	New Submission	12-Nov-25	Non-benefit
	lebrikizumab	Ebglyss	atopic dermatitis	New Submission	November 19, 2025	Non-benefit
	clascoterone	Winlevi	Acne vulgaris	New Submission	19-Nov-25	Non-benefit
	remdesivir	Veklury	COVID-19 in hospitalized patients	New Submission	26-Nov-25	Non-Benefit
	remdesivir	Veklury	COVID-19 in non-hospitalized patients	New Submission	26-Nov-25	Non-benefit
	trofinetide	Daybue	Rett syndrome (RTT)	New Submission	01-Dec-25	Non-benefit
	cannabidiol	Epidiolex	Seizures associated with Tuberous Sclerosis Complex (TSC)	New Submission	December 3, 2025	Limited Coverage

cannabidiol	Epidiolex	Lennox-Gastaut Syndrome (LGS)	New Submission	December 3, 2025	Limited Coverage
cannabidiol	Epidiolex	Dravet Syndrome (DS)	New Submission	December 3, 2025	Limited Coverage
tenofovir alafenamide	Vemlidy	Chronic Hepatitis B	Resubmission	03-Dec-25	Limited Coverage
aripiprazole	Abilify Asimtufii	Schizophrenia	New Submission	17-Dec-25	Limited Coverage
belumosudil	Rezurock	chronic graft-versus-host disease (GVHD)	New Submission	December 17, 2025	Limited Coverage
mylife Loop	hybrid closed-loop system	Diabetes management, type 1	Line Extension	17-Dec-25	Limited Coverage
semaglutide	Wegovy	Reduce the risk of major adverse cardiovascular events	Resubmission	18-Dec-25	Non-Benefit

2025 Patient and Caregiver Input Summary

Drug Details			Patient Responses to calls for input		
Generic Name	Trade Name	Indication	Patient	Caregiver	Patient Group
pegcetacoplan	TBC	geographic atrophy secondary to age-related macular degeneration	0	0	0
iptacopan	TBC	paroxysmal nocturnal hemoglobinuria (PNH)	0	0	1
rozanolixizumab	TBC	generalized myasthenia gravis (gMG)	0	0	0
donanemab	TBC	Alzheimer's disease	3	7	1
omaveloxolone	TBC	Friedreich's Ataxia	3	61	1

crovalimab	TBC	paroxysmal nocturnal hemoglobinuria (PNH)	0	0	1
ruxolitinib	Opzelura	nonsegmental vitiligo	0	0	0
guselkumab	Tremfya	UC	0	0	2
bimekizumab	Bimzelx	hidradenitis suppurativa	0	0	1
teprotumumab	TBC	Chronic thyroid eye disease (TED)	0	0	0
teprotumumab	TBC	Active thyroid eye disease (TED)	1	0	1
trofinetide	Daybue	Rett syndrome (RTT)	2	19	1
semaglutide	Wegovy	weight management and prevention of major adverse cardiovascular events (MACE)	96	7	2
elafibranor	TBC	primary biliary cholangitis (PBC)	0	0	0
cipaglucosidase alfa with miglustat	TBC	Pompe disease	3	0	1
fecal microbiota	TBC	c.diff infection prevention	0	0	1
daridorexant	Quviviq	insomnia	1	0	3
dupilumab	Dupixent	CRwNP	0	0	1
dupilumab	Dupixent	COPD	0	0	2
dupilumab	Dupixent	prurigo nodularis (PN)	0	0	1
nemolizumab	TBC	prurigo nodularis (PN)	0	0	0
guselkumab	Tremfya	Crohn's disease	0	0	1
relugolix, estradiol, and norethindrone acetate	Myfembree	heavy menstrual bleeding associated with uterine fibroids	1	0	0

Hybrid closed loop systems for the management of diabetes mellitus	Misc	Diabetes mellitus requiring insulin therapy	804	265	5
tofersen	Qalsody	ALS	0	0	2
nemolizumab	TBC	Atopic dermatitis (AD)	0	0	1
teplizumab	Tzielid	delay onset of stage 3 type 1 diabetes	2	6	3
mirikizumab	TBC	Crohn's disease (CD)	2	0	2
odevixibat	Bylvay	Alagille syndrome-associated cholestatic pruritus	0	0	2
bulevirtide	Hepcludex	Hepatitis delta virus (HPD) infection	0	0	1
pegunigalsidase alfa	TBC	Fabry disease	0	0	0
risankizumab	Skyrizi	Ulcerative colitis (UC)	0	0	2
lemborexant	Dayvigo	insomnia	1	0	2
risperidone	Okedi	schizophrenia in adults	0	0	0
vanzacaftor, tezacaftor, deuterivacaftor	Alyftrek	Cystic Fibrosis	0	0	1
delgocitinib	Anzupgo	Chronic hand eczema in adults	0	0	1
roflumilast	Zoryve	atopic dermatitis (AD)	2	0	2
efgartigimod alfa	Vyvgart	chronic inflammatory demyelinating polyneuropathy (CIDP) in adults	0	0	1
finerenone	Kerendia	heart failure in adults	1	0	0
osilodrostat	Isturisa	Endogenous Cushing's disease in adults	1	0	0
mepolizumab	Nucala	Chronic obstructive pulmonary disease (COPD) in adults	0	0	1
lutrisiran	Amvuttra	transthyretin-amyloidosis in adult	3	0	0

		patients with cardiomyopathy.			
olezarsen	TBC	familial chylomicronemia syndrome (FCS) in adults	0	0	0
maralixibat	Livmarli	progressive familial intrahepatic Cholestasis (PFIC) in patients three months of age and older	0	0	0
avacincaptad pegol	Izervay	Non-foveal geographic atrophy (GA) secondary to age-related macular degeneration (AMD)	0	0	1
lecanemab	Leqembi	Alzheimer's disease	3	3	1
seladelpar	Lyvdelzi	primary biliary cholangitis (PBC) in adults	22	0	0
palopegteriparatide	TBC	chronic hypoparathyroidism (HypoPT) in adults	9	0	1
epinephrine	Neffy	emergency treatment of type 1 allergic reactions, including anaphylaxis in adult and pediatric patients	3	1	0
vamorolone	Agamree	Duchenne muscular dystrophy in patients 4 years of age and older	0	0	1
nipocalimab	Imaavy	Generalized myasthenia gravis (gMG) in adults and adolescent patients	0	0	1

2024 Reports

Type, Timelines, and Number of Completed Drug Submission Reviews, by Quarter

Reporting Period	Review Type ¹	Target Timeline (months)	Reviews Completed ²	Actual Review Times (months)			Reviews Meeting Target Timeline (%)
				Avg.	Min.	Max.	
Q1 2024	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	4	9.07	1.75	14.13	50%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	3	12.3	11.49	13.79	66%
	Other ³	N/A	3	N/A	N/A	N/A	N/A
	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	4	7.4	1.55	12.49	75%

Q2 2024	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	6	16.21	8.92	27.79	50%
	Other	N/A	0	N/A	N/A	N/A	N/A
Q3 2024	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	6	8.5	4.39	22.01	83%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	4	13.54	11.23	17.26	50%
	Other	N/A	7	N/A	N/A	N/A	N/A
Q4 2024	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	6	7.74	0.65	15.85	66%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	9	15.13	10.65	20.55	22%
	Other	N/A	3	N/A	N/A	N/A	N/A
2024 YTD Total	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	20	8.17	1.55	22.01	70%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	22	14.29	11.23	27.79	41%
	Other	N/A	13	N/A	N/A	N/A	N/A
	Submissions with Timeliness ⁴	6-12	44	11.35	1.55	27.49	52%

¹ Review types are defined in "[The Drug Review Process in B.C. – Detailed](#)" on the PharmaCare website.

² A submission review is complete on the date of the formulary decision or the coverage effective date.

³ The 'Other' category covers submissions not subject to target timelines.

2024 Drug Review Decisions Summary

	Generic Name	Trade Name	Indication	Submission Type	Decision Date	Decision
Q1	ozanimod	Zeposia	ulcerative colitis	New Submission	January 16, 2024	Limited Coverage Benefit
	riluzole	rilutek	ALS	Generic	February 1, 2024	Regular Benefit - EDRD
	semaglutide 0.68 mg/mL	Ozempic	Type 2 Diabetes	Line Extension	February 6, 2024	Limited Coverage
	Icosapent	Vascepa	LDL - Reverse decision from NB to LC	Ministry Initiated	February 6, 2024	Limited Coverage

	finerenone	Kerendia	Chronic Kidney Disease	New Submission	February 27, 2024	Limited Coverage
	avacopan	Tavneos	Antineutrophil cytoplasmic antibody-associated vasculitis	New Submission	February 27, 2024	Non-Benefit
	pegcetacoplan	Empaveli	Paroxysmal nocturnal hemoglobinuria	New Submission	March 6, 2024	Case by Case EDRD
	lurasidone	Latuda	Bipolar depression	Ministry-initiated	March 7, 2024	Limited Coverage
	lemborexant	Dayvigo	Insomnia	New Submission	March 14, 2024	Non-Benefit
	deferiprone	Ferriprox	transfusional iron overload due to sickle cell disease or other anemias	New Submission	March 14, 2024	Non-Benefit
Q2	tazarotene	Arazlo	topical treatment of acne vulgaris in patients 10 years of age and older.	Modification of Coverage	April 9, 2024	Limited Coverage
	ravulizumab	Ultomiris	anti-acetylcholine receptor (AChR) antibody-positive generalized Myasthenia Gravis (gMG)	New Submission	April 17, 2024	Non-Benefit
	eptinezumab	Vyepiti	Migraine	New Submission	April 23, 2024	Limited Coverage
	difelikefalin	Korsuva	Chronic Kidney Disease associated pruritus	New Submission	April 30, 2024	Non-Benefit
	filgrastim injection	Nypozi	for the prevention and treatment of neutropenia	Biosimilar	May 14, 2024	Limited Coverage
	estradiol	Imvexxy	Dyspareunia	New Submission	May 14, 2024	Regular Benefit
	nirmatrelvir/ ritonavir	Paxlovid	Mild-to-moderate COVID-19, treatment	New Submission	May 28, 2024	Plan Z (Assurance Plan) benefit
	ustekinumab biosimilar	Jamteki	Plaque Psoriasis, Psoriatic Arthritis	Biosimilar	May 30, 2024	Limited Coverage
	risankizumab	Skyrizi	Crohns's Disease	New Submission	May 30, 2024	Limited Coverage
	budesonide foam	Uceris	for active or moderate distal ulcerative colitis	Line Extension	June 18, 2024	Regular Benefit

	Etanercept biosimilar	Rymti	Multiple	Biosimilar	June 25, 2024	Limited Coverage
Q3	Adalimumab	Multiple	Non-Infectious Uveitis	Therapeutic Review	July 3, 2024	Limited Coverage
	adalimumab	Hyrimoz	Multiple	Line Extension	03-Jul-24	Limited Coverage
	lumasiran	Oxlumo	Primary hyperoxaluria type 1	New Submission	July 16, 2024	Case by Case EDRD
	tildrakizumab	Ilumya	Plaque psoriasis	Re-submission	08-Jul-24	Non-Benefit
	sodium phenylbutyrate and ursodoxicoltaurine	Albrioza	Amyotrophic lateral sclerosis	delisting	19-Jul-24	Delisting
	deucravacitinib	Sotyktu	adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy	New Submission	July 25, 2024	Non-Benefit
	tiotropium bromide and tiotropium	Spiriva Handihaler and Lupin	COPD	Ministry Initiated	05-Aug-24	Regular Benefit
	foslevodopa-foscarbidopa	Vyalev	Parkinson's disease	New Submission	August 20, 2024	Limited Coverage
	glecaprevir/pibrentasvirr	Maviret	MI - 50mg-20 mg sachet for Pediatrics (3 to less than 18 years old)	Therapeutic Review	20-Aug-24	Limited Coverage
	denosumab	Jubbonti	Multiple Indications	Biosimilar	29-Aug-24	Limited Coverage
	denosumab	Wyost	Plan P Coverage	New submission	29-Aug-24	Plan P coverage
	alendronate and risedronate	bisphosphonates	osteoporosis	Ministry Initiated	29-Aug-24	Regular Benefit
	dalbavancin hydrochloride	Xydalba	Acute bacterial skin and skin structure infections	New Submission	September 17, 2024	Non-Benefit
	upadacitinib	Rinvoq CD	Crohns disease	New Submission	September 17, 2024	Limited Coverage
ustekinumab biosimilar	WEZLANA	plaque psoriasis (PsO), psoriatic arthritis (PsA), Crohn's disease (CD), and	Biosimilar	September 17, 2024	Limited Coverage	

			ulcerative colitis (UC)			
	ustekinumab	Steqeyma	Multiple	Biosimilar	17-Sep-24	Limited Coverage
	alpha1-proteinase inhibitor (delisting) - Ministry Initiated	Prolastin C	Alpha1-antitrypsin deficiency (alpha-1)	Ministry Initiated	September 18, 2024	Delisting
Q4	upadacitinib	Rinvoq UC	ulcerative colitis	New Submission	October 3, 2024	Non-Benefit
	ethinyl estradiol and etonogestrel vaginal ring contraceptive	NuvaRing	Contraceptive	Ministry Initiated	October 15, 2024	Regular Benefit
	vericiguat	Verquvo	Heart failure	New Submission	October 15, 2024	Limited Coverage
	norethindrone acetate and ethinyl estradiol	Lolo	Contraceptive	Ministry Initiated	15-Oct-24	Regular benefit under Plan Z and Plan C
	elexacaftor/tezacaftor/ivacaftor	Trikafta	Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older	New Submission	Nov. 6, 2024	Covered under EDRD program
	avatrombopag	Doptelet	thrombocytopenia in adult patients with chronic immune thrombocytopenia	New Submission	Nov. 7, 2024	Do Not List
	berotralstat (EDRD)	Orladeyo	Hereditary angioedema (HAE)	New Submission	Nov. 7, 2024	EDRD
	cenobamate	Xcopri	Epilepsy, partial-onset seizures	New Submission	Nov. 14, 2024	Non-Benefit
	mirikizumab	Omvoh	ulcerative colitis	New Submission	Nov. 19, 2024	Limited Coverage

mavacamten	Camzyos	Obstructive hypertrophic cardiomyopathy	New Submission	Nov. 26, 2024	Limited Coverage
atogepant	Qulipta	Episodic Migraine, prevention	New Submission	December 3, 2024	Limited Coverage
atogepant	Qulipta	Chronic Migraine, prevention	New Submission	03-Dec-24	Limited Coverage
drospirenone	Slynd	Contraceptive, oral	New Submission	December 10, 2024	Regular benefit under Plan Z and Plan C
Diabetic Pen Needles	Nanofine Plus Diabetic Pen Needles	Diabetic Supplies	Diabetic Supplies	December 10, 2024	Eligible benefit
roflumilast cream	Zoryve	Plaque psoriasis	New Submission	December 12, 2024	Non-Benefit
tralokinumab	Adtralza	atopic dermatitis (AD), patients aged 12 and up	New Indication	December 17, 2024	Non-Benefit
somapacitan	Sogroya	Growth Hormone Deficiency (GHD)	New Submission	December 17, 2024	Non-Benefit
vutrisiran	Amvuttra	Hereditary transthyretin mediated amyloidosis	New Submission	December 19, 2024	EDRD

2024 Patient and Caregiver Input Summary

Drug Details			Patient Responses to calls for input		
Generic Name	Trade Name	Indication	Patient	Caregiver	Patient Group
inclisiran	Leqvio	heterozygous familial hypercholesterolemia (HeFH)	57	0	0

inclisiran	Leqvio	non-familial hypercholesterolemia (nFH) with atherosclerotic cardiovascular disease (ASCVD)	22	3	0
infliximab	Remsima	Crohn's disease	1	0	1
infliximab	Remsima	ulcerative colitis	1	0	1
cannabidiol	Epidiolex	seizures associated with Tuberous sclerosis complex (TSC)	0	0	0
cannabidiol	Epidiolex	Seizures associated with Lennox-Gastaut Syndrome (LGS)	0	0	0
cannabidiol	Epidiolex	Seizures associated with Dravet syndrome (DS)	0	0	0
bimekizumab	Bimzelx	Active ankylosing spondylitis	0	0	2 (1 is joint submission from 4 groups)
bimekizumab	Bimzelx	active psoriatic arthritis (PsA)	0	0	2
glecaprevir-pibrentasvir	Maviret	chronic hepatitis C virus (HCV) infection in pediatric patients 3 years of age and older and weighing at least 12 kg.	0	2	1
risperidone	TBC	schizophrenia in adults	0	0	0
lebrikizumab	TBC	atopic dermatitis (AD)	1	0	1
insulin icodec	Awigli	type 2 diabetes	0	0	2
evolocumab	Repatha	primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD).	4	0	0
ivaroxaban	Xarelto	venous thromboembolic events (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, and children and	0	0	0

		adolescents aged less than 18 years			
atogepant	Qulipta	chronic migraine prevention	6	1	0
burosumab	Crysvita	X-linked hypophosphatemia in adults	0	0	0
etrasimod	Velsipity	Ulcerative colitis (UC)	0	0	1
remdesivir	Velklury		8	2	1
fidaxomicin	Dificid	First line treatment of C. difficile infection	1	0	1
tofacitinib	generics	Active ankylosing spondylitis (AS)	0	0	2
tofacitinib	generics	Active psoriatic arthritis (PsA)	1	0	2
elexacaftor/tezacaftor/ivacaftor and ivacaftor	Trikafta	Cystic fibrosis (CF), F508del or responsive CFTR mutation, 2 years and older	1	3	1
baricitinib	Olumiant	Severe alopecia areata in adults	1	1	1
clindamycin plus benzoyl peroxide and adapalene	Cabtreo	topical treatment of acne vulgaris in patients 9 years of age and older.	1	1	1
sotatercept	Winrevair	Pulmonary arterial hypertension (WHO group 1)	4	0	1
eplontersen	Wainua	polyneuropathy (PN) associated with hereditary transthyretin-mediated amyloidosis (hATTR) in adults	0	0	0
danicopan	Voydeya	Paroxysmal nocturnal hemoglobinuria (PNH) post NOC	0	0	1
ferric carboxymaltose	Ferinject	Iron deficiency anemia	0	2	2
ferric carboxymaltose	Ferinject	Iron deficiency in adult patients with heart failure	0	0	0

spesolimab	Spevigo	generalized pustular psoriasis (GPP)	0	0	1
ravulizumab	Ultomiris	generalized myasthenia gravis (gMG)	0	0	0
olopatadine hcl/ mometasone furoate	Ryaltris	seasonal allergic rhinitis	2	0	0
ruxolitinib	Opzelura	AD	0	0	1
zilucoplan	Zilbrysq	gMG	0	0	0
faricimab	Vabysmo	macular edema secondary to retinal vein occlusion	0	0	2
garadacimab	Andembry	hereditary angioedema (HAE)	0	0	1
pegcetacoplan	TBC	geographic atrophy secondary to age-related macular degeneration	0	0	0

2023 Reports

Type, Timelines, and Number of Completed Drug Submission Reviews, by Quarter

Reporting Period	Review Type ¹	Target Timeline (months)	Reviews Completed ²	Actual Review Times (months)			Reviews Meeting Target Timeline (%)
				Avg.	Min.	Max.	
	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	5	1.98	1	3.5	100%

Q1 2023	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	11	23.3	14	30	0%
	Other ³	N/A	0	N/A	N/A	N/A	N/A
Q2 2023	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	6	6.5	1.8	9.5	83%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	12	22.5	11	35.6	0%
	Other	N/A	1	6	6	6	6
Q3 2023	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	6	6.9	1.2	9.5	83%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	7	20.2	11.9	35.5	14.3%
	Other	N/A	2	N/A	N/A	N/A	N/A
Q4 2023	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	5	11.9	1.8	23.9	20%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	5	15.4	0.65	30.3	20%
	Other	N/A	5	N/A	N/A	N/A	N/A
2023 YTD Total	Priority	6	0	N/A	N/A	N/A	N/A
	Standard	9	17	5.3	1	9.5	94%
	Priority Complex	9	0	N/A	N/A	N/A	N/A
	Complex	12	30	22	11	35.6	3%
	Other	N/A	3	N/A	N/A	N/A	N/A
	Submissions with Timeliness ⁴	6-12	47	17.2	1	35.6	34%

¹ Review types are defined in “[The Drug Review Process in B.C. – Detailed](#)” on the PharmaCare website.

² A submission review is complete on the date of the formulary decision or the coverage effective date.

³ The ‘Other’ category covers submissions not subject to target timelines.

2023 Drug Review Decisions Summary

	Generic Name	Trade Name	Indication	Submission Type	Decision Date	Decision
Q1	dapagliflozin	Forxiga	HFrEF & T2DM	Criteria Modification	05-Jan-23	Regular Benefit
	empagliflozin	Jardiance	Type 2 Diabetes mellitus	Criteria Modification	05-Jan-23	Limited Coverage
	semaglutide	Wegovy	weight management	Criteria Modification	05-Jan-23	Limited Coverage

	insulin aspart biosimilar	Kirsty	Diabetes	Biosimilar	24-Jan-23	Regular Benefit
	bimekizumab	Bimzelx	Psoriasis, moderate to severe plaque	New Submission	31-Jan-23	Limited Coverage
	fostamatinib	Tavalisse	Chronic immune thrombocytopenia	New Submission	31-Jan-23	Non-Benefit
	semaglutide	Rybelsus	Diabetes mellitus, type 2	New Submission	31-Jan-23	Non-Benefit
	eculizumab	Soliris	Neuromyelitis optica spectrum disorder	New Indication	10-Feb-23	Non-Benefit
	eculizumab	Soliris	Myasthenia Gravis (gMG), adults	New Indication	10-Feb-23	Non-Benefit
	incobotulinumtoxin A	Xeomin	Chronic sialorrhea associated with neurological disorders	New Submission	14-Feb-23	Non-Benefit
	amlodipine liquid Line Extension	PDP-amlodipine	Hypertension / angina	Line Extension	28-Feb-23	Limited Coverage
	glycopyrrolate	Cuvposa	chronic severe drooling, neurologic (pediatric)	New Submission	28-Feb-23	Non-Benefit
	voretigene neparvovec	Luxturna	Vision loss, inherited retinal dystrophy	New Submission	28-Feb-23	EDRD (case by case)
	luspatercept	Reblozyl	Myelodysplastic syndromes-associated anemia	New Submission	14-Mar-23	Non-Benefit
	luspatercept	Reblozyl	beta-thalassemia associated anemia	New Submission	14-Mar-23	Limited Coverage
	amifampridine	Ruzurgi	Lambert-Eaton myasthenic syndrome	New Submission	28-Mar-23	Limited Coverage
Q2	sebelipase alfa	Kanuma	lysosomal acid lipase deficiency	New Submission	5-Apr-23	EDRD (case by case)
	mesalamine oral delayed release tablet 500 mg	Mezera	for active or moderate ulcerative colitis	Line Extension	11-Apr-23	Non-Benefit
	galcanezumab	Emgality	Prevention of migraine	New Submission	11-Apr-23	Limited Coverage Criteria
	ustekinumab	Stelara/Stelara IV	ulcerative colitis	New Indication	17-Jan-23	Non-Benefit
	tretinoin gel Line Extension	Retin-A Micro	Acne	New Submission	March 7, 2023 (non benefit)	Non-Benefit

	mecasermin	Increlex	Severe primary insulin-like growth factor-1 deficiency	New Submission	April 27, 2023	EDRD (case by case)
	somatogon	Ngenla	Growth hormone deficiency	New Submission	May 2, 2023	Non-Benefit
	safinamide	Onstryv	Parkinson's disease	New Submission	May 4, 2023	Non-Benefit
	cariprazine	Vraylar	Bipolar disorder	New Submission	May 4, 2023	Non-Benefit
	cariprazine	Vraylar	Schizophrenia	New Submission	May 4, 2023	Non-Benefit
	tafamidis	Vyndamax	transthyretin-mediated amyloidosis	Line Extension	May 11, 2023	EDRD (case by case)
	trihexanoin	Dojolvi	Long-chain fatty acid oxidation disorders	New Submission	May 23, 2023	EDRD (case by case)
	insulin glargine	Semglee	Insulin biosimilar	New Submission	May 25, 2023	Limited Coverage
	caplacizumab (EDRD)	Cablivi	Acquired thrombotic thrombocytopenic purpura (aTTP)	Resubmission	May 26, 2023	EDRD (case by case)
	mesalamine	Octasa	ulcerative colitis	Line Extension	May 30, 2023	Non-Benefit
	prasterone	Intrarosa	Postmenopausal vulvovaginal atrophy	New Submission	May 30, 2023	Non-Benefit
	ospemifene	Osphena	Postmenopausal dyspareunia, vaginal dryness	New Submission	May 30, 2023	Non-Benefit
	enoxaparin sodium (Biosimilar)	Elonox / Elonox HP	deep vein thrombosis	Biosimilar	June 1, 2023	Limited Coverage
	Givosiran	Givlaari	Acute Hepatic Porphyria	New Submission	June 22, 2023	EDRD (case by case)
Q3	enoxaparin sodium (Biosimilar)	Elonox / Elonox HP	deep vein thrombosis	Biosimilar	June 1, 2023	Limited Coverage Criteria
	givosiran	Givlaari	Treatment of acute hepatic porphyria (AHP) in adults	New Submission	June 22, 2023	Non-Benefit, Exceptional Case by Case

somatropin (line extension)	Norditropin FlexPro	Growth hormone deficiency	Line Extension	July 4, 2023	Limited Coverage Criteria
icosapent ethyl	Vascepa	Ischemic events in statin-treated patients	New Submission	July 6, 2023	Non-Benefit
estradiol and progesterone	Bijuva	Vasomotor symptoms associated with menopause	New Submission	July 6, 2023	Non-Benefit
sodium phenylbutyrate and ursodoxicoltaurine (EDRD)	Albrioza	Amyotrophic lateral sclerosis (ALS)	New Submission	July 19, 2023	Limited Coverage Criteria
pancrelipase	Pancrease	Treatment of pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis, or any other medically defined pancreatic disease that might require pancreatic enzyme therapy.	Line Extension	July 25, 2023	Non-Benefit
Flash Glucose Monitoring System	Freestyle Libre	Diabetes - Ministry Initiated	Resubmission	August 1, 2023	Limited Coverage
pitolisant hydrochloride	Wakix	Narcolepsy	New Submission	August 15, 2023	Non-Benefit
dexamethasone intravitreal implant (CADTH resubmission)	Ozurdex	Diabetic Macular Edema	Resubmission	August 17, 2023	Non-Benefit - EDRD
onabotulinumtoxin A (50, 100, 200 unit vial)	Botox	Various	Ministry Initiated	August 17, 2023	Completed

	edaravone oral (EDRD)	Radicava	Amyotrophic lateral sclerosis (ALS)	New Submission	August 18, 2023	Limited Coverage EDRD
	amifampridine phosphate	Firdapse	Lambert-Eaton Myasthenic Syndrome, adults	New Submission	September 7, 2023	Limited Coverage
	ravulizumab	Ultomiris	Paroxysmal nocturnal hemoglobinuria	New Submission	September 22, 2023	Non-Benefit
	ravulizumab (EDRD)	Ultomiris	Atypical hemolytic uremic syndrome	New Submission	September 22, 2023	Non-Benefit
Q4	mepolizumab/benralizumab	Nucala/Fasenra	Asthma: Modification of LC criteria	Modification of Coverage	17-Oct-23	Limited Coverage Criteria
	dupilumab	Dupixent	Asthma (age 6 to <12 years, add on therapy)	New Submission	October 17, 2023	Limited Coverage Criteria
	avalglucosidase alfa	Nexviazyme	Pompe disease	New Submission	October 30, 2023	Non-Benefit
	satralizumab	Enspryng	Neuromyelitis optica spectrum disorder	New Submission	November 1, 2023	Limited Coverage Criteria
	Ministry initiated: rituximab and tocilizumab	Multiple biosimilars	NMOSD	Ministry Initiated	November 1, 2023	Limited Coverage Criteria
	Dexcom Continuous Glucose Monitor	Dexcom G7	Diabetes	New Submission	November 7, 2023	Limited Coverage Criteria
	ruxolitinib	Jakavi	Graft versus host disease (acute)	New Submission	November 23, 2023	Limited Coverage Criteria
	ruxolitinib	Jakavi	Graft versus host disease (chronic)	New Submission	November 23, 2023	Limited Coverage Criteria
	guselkumab injection	Tremfya	Psoriatic Arthritis	New Submission	November 28, 2023	Non-Benefit

rivaroxaban	Xarelto	Multiple Indications LC to RB	Ministry Initiated	07-Dec-23	Regular benefit
romosozumab	Evenity	Osteoporosis, postmenopausal women	New Submission	December 14, 2023	Limited Coverage
tezepelumab	Tezspire	Asthma	New Submission	December 14, 2023	Limited Coverage
elexacaftor/tezacaftor/ivacaftor	Trikafta	Cystic fibrosis, F508del CFTR mutation, 2 years and older	Modification of Coverage	December 14, 2023	EDRD
adalimumab	Yuflyma	Multiple Indications	Biosimilar	December 19, 2023	Limited Coverage
adalimumab	Hadlima	Multiple Indications	Biosimilar	December 19, 2023	Limited Coverage

2023 Patient and Caregiver Input Summary

Drug Details			Patient Responses to calls for input		
Generic Name	Trade Name	Indication	Patient	Caregiver	Patient Group
lurasidone	Latuda and generics	bipolar 1 disorder	0	0	0

pegcetacoplan	Empaveli	Paroxysmal nocturnal hemoglobinuria (PNH)	0	0	2
ferumoxytol	Feraheme	Iron deficiency anemia	0	0	0
difelikefalin	Korsuva	Chronic Kidney Disease associated pruritus	0	0	0
mavacamten	Camzyos	Obstructive hypertrophic cardiomyopathy	1	0	1
deucravacitinib	Sotyktu	Plaque psoriasis, moderate to severe	0	0	1
risankizumab	Skyrizi	Crohn's disease	0	0	2
ravulizumab	Ultomiris	AChR antibody-positive generalized Myasthenia Gravis	0	0	0
avacopan	Tavneos	Antineutrophil cytoplasmic antibody-associated vasculitis	0	2	1
vericiguat	Verquvo	Heart failure	0	0	1
upadacitinib	Rinvoq	Ankylosing spondylitis	0	0	1
palovarotene	Sohonos	Fibrodysplasia Ossificans Progressiva	0	0	1
selumetinib	Koselugo	Neurofibromatosis type 1	5	6	1
foslevodopa foscarnidopa	TBC	Parkinson's disease	0	0	1
atogepant	Qulipta	Prevention of episodic migraine	28	3	1
roflumilast	Zoryve	Plaque psoriasis	1	0	1 (joint submission of three patient groups)
cenobamate	TBC	Epilepsy, partial onset seizures	0	0	0
adalimumab	biosimilars (TR)	Non-infectious uveitis	0	0	0

mirikizumab	TBC	ulcerativr colitis	3	0	2
setmelanotide	Imcivree	Bardet-Biedly syndrom-associated obesity	0	0	1
dupilumab	Dupixent Peds	atopic dermatitis, ages 6 months to 12 years	1	4	1
elexacaftor/tezacaftor/ivacaftor and ivacaftor	Trikafta	Cystic fibrosis, 2 to 5 years	0	1	1
maralixibat	Livmarli	Alagille syndrome-associated cholestatic pruritus	0	0	0
efgartigimod alfa	Vyvgart	generalized myasthenia gravis (gMG)	0	0	0
evinacumab	TBC	Homozygous familial hypercholesterolemia (HoFH)	20	0	0
somapacitan	Sogroya	growth hormone deficiency	0	0	0
secukinumab	Cosentyx	Hidradenitis suppurativa	0	0	0
tralokinumab	Adtralza	atopic dermatitis	0	0	1
avatrombopag	Doptelet	chronic immune thrombocytopenia (ITP)	0	0	0
upadacitinib	Rinvoq	Crohn's disease	0	0	2
odevixibat	Bylvay	progressive familial intrahepatic Cholestasis (PFIC)	0	0	0
vutrisiran	Amvuttra	hereditary transthyretin mediated amyloidosis	0	0	0
clascoterone	Winlevi	acne vulgaris	1	0	2
metreleptin	Myalepta	leptin deficiency in lipodystrophy	0	0	0
belumosudil	Rezurock	chronic graft-versus-host disease (cGVHD)	0	0	1
nirmatrelvir-ritonavir	Paxlovid	COVID-19 in patients at high risk for progression to severe	13	2	2

fidanacogene elaparvovec	TBC	moderately severe to severe hemophilia B	0	0	1
--------------------------	-----	--	---	---	---